Product Description
Laquinimod is a novel immunomodulatory agent, in development as a potential disease-modifying treatment for multiple sclerosis (MS).
Mechanisms of Action: AhR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: European Medicines Agency | Russia
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Autoimmune Disease Unspecified|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 21LAQ01 | P1 |
Completed |
Healthy Volunteers|Autoimmune Disease Unspecified |
2023-01-19 |
28% |